References
- FolkmanJKlagsbrunMAngiogenic factorsScience198723547874424472432664
- SamantRSShevdeLARecent advances in anti-angiogenic therapy of cancerOncotarget20112312213421399234
- FerraraNVascular endothelial growth factor as a target for anticancer therapyOncologist20049 Suppl 121015178810
- TakahashiSVascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapyBiol Pharm Bull201134121785178822130231
- CrawfordYFerraraNVEGF inhibition: insights from preclinical and clinical studiesCell Tissue Res2009335126126918766380
- CaoYPositive and negative modulation of angiogenesis by VEGFR1 ligandsSci Signal2009259re119244214
- Escudero-EsparzaAMartinTADaviesMLJiangWGPGF isoforms, PlGF-1 and PlGF-2, in colorectal cancer and the prognostic significanceCancer Genomics Proteomics20096423924619657001
- CarmelietPJainRKMolecular mechanisms and clinical applications of angiogenesisNature2011473734729830721593862
- FerraraNHillanKJNovotnyWBevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapyBiochem Biophys Res Commun2005333232833515961063
- HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
- ChuEAn update on the current and emerging targeted agents in metastatic colorectal cancerClin Colorectal Cancer201211111321752724
- LiXLeeCTangZVEGF-B: a survival, or an angiogenic factor?Cell Adh Migr20093432232719684473
- CarmelietPMoonsLLuttunASynergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditionsNat Med20017557558311329059
- KopetzSHoffPMMorrisJSPhase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistanceJ Clin Oncol201028345345920008624
- KorpantyGSullivanLASmythECarneyDNBrekkenRAMolecular and clinical aspects of targeting the VEGF pathway in tumorsJ Oncol2010201065232020628530
- OlofssonBKorpelainenEPepperMSVascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cellsProc Natl Acad Sci U S A1998952011709117149751730
- RibattiDThe discovery of the placental growth factor and its role in angiogenesis: a historical reviewAngiogenesis200811321522118568405
- HilmiCGuyotMPagèsGVEGF spliced variants: possible role of anti-angiogenesis therapyJ Nucleic Acids2012201216269222013509
- ChuQSAflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factorsExpert Opin Biol Ther20099226327119236257
- OlofssonBPajusolaKvon EulerGChilovDAlitaloKErikssonUGenomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoformJ Biol Chem19962713219310193178702615
- FischerCMazzoneMJonckxBCarmelietPFLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?Nat Rev Cancer200881294295619029957
- HamerlikPLathiaJDRasmussenRAutocrine VEGF-VEGFR2- Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growthJ Exp Med2012209350752022393126
- Van de VeireSStalmansIHeindryckxFFurther pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye diseaseCell2010141117819020371353
- FischerCJonckxBMazzoneMAnti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vesselsCell2007131346347517981115
- BaisCWuXYaoJPlGF blockade does not inhibit angiogenesis during primary tumor growthCell2010141116617720371352
- LogesSSchmidtTCarmelietPAntimyeloangiogenic therapy for cancer by inhibiting PlGFClin Cancer Res200915113648365319470735
- YaoJWuXZhuangGExpression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacyProc Natl Acad Sci U S A201110828115901159521709213
- ZhangFTangZHouXVEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesisProc Natl Acad Sci U S A2009106156152615719369214
- TolJPunkCJMonoclonal antibodies in the treatment of metastatic colorectal cancer: a reviewClin Ther201032343745320399983
- Avastin®(bevacizumab) [prescribing information]South San Francisco, CAGenentech, Inc2013
- JainRKNormalization of tumor vasculature: an emerging concept in antiangiogenic therapyScience20053075706586215637262
- Van der VeldtAALubberinkMBahceIRapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugsCancer Cell2012211829122264790
- MaitlandMLLouXJRamirezJVascular endothelial growth factor pathwayPharmacogenet Genomics201020534634920124951
- JainRKdi TomasoEDudaDGLoefflerJSSorensenAGBatchelorTTAngiogenesis in brain tumoursNat Rev Neurosci20078861062217643088
- KeunenOJohanssonMOudinAAnti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastomaProc Natl Acad Sci U S A201110893749375421321221
- HolashJDavisSPapadopoulosNVEGF-Trap: a VEGF blocker with potent antitumor effectsProc Natl Acad Sci U S A20029917113931139812177445
- TewWPGordonMMurrenJPhase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumorsClin Cancer Res201016135836620028764
- PapadopoulosNMartinJRuanQBinding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis201215217118522302382
- TengLSJinKTHeKFZhangJWangHHCaoJClinical applications of VEGF-trap (aflibercept) in cancer treatmentJ Chin Med Assoc201073944945620875616
- Van CutsemETaberneroJLakomyRAddition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimenJ Clin Oncol201230283499350622949147
- ZALTRAP®(ziv-aflibercept) [prescribing information]Bridgewater, NJRegeneron Pharmaceuticals, Inc/sanofi-aventis US LLC2012
- SanofiA Multinational, randomized, double-blind study, comparing the efficacy of aflibercept once every 2 weeks versus placebo in patients treated with gemcitabine for metastatic pancreatic cancer (VANILLA)ClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine2012 Available from: http://www.clinicaltrials.gov/ct2/show/NCT00574275. NLM identifier: NCT00574275Accessed April 26, 2013
- SanofiA multicenter, randomized, double blind study comparing the efficacy and safety of aflibercept versus placebo administered every 3 weeks in patients treated with docetaxel/prednisone for metastatic androgen-independent prostate cancer (VENICE)ClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine2012 Available from: http://clinicaltrials.gov/show/NCT00519285. NLM identifier: NCT00519285Accessed April 26, 2013
- SanofiA multinational, randomized, double-blind study comparing aflibercept versus placebo in patients treated with second-line docetaxel after failure of one platinum based therapy for locally advanced or metastatic non-small-cell lung cancer (VITAL)ClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine2012 Available from: http://clinicaltrials.gov/show/NCT00532155. NLM identifier: NCT00532155Accessed April 26, 2013
- Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer [webpage on the Internet]PR Newswire3102011 Available from: http://www.prnewswire.com/news-releases/sanofi-aventis-and-regeneron-report-top-line-results-from-phase-iii-study-with-aflibercept-vegf-trap-in-second-line-non-small-cell-lung-cancer-117757228.htmlAccessed November 30, 2012
- JinKShenYHeKXuZLiGTengLAflibercept (VEGF Trap): one more double edged sword of anti-VEGF therapy for cancer?Clin Transl Oncol201012852653220709650
- SpratlinJRamucirumab (IMC-1121B): monoclonal antibody inhibition of vascular endothelial growth factor receptor-2Curr Oncol Rep20111329710221222245
- KrupitskayaYWakeleeHARamucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancerCurr Opin Investig Drugs2009106597605
- GrotheyAGalanisETargeting angiogenesis: progress with anti-VEGF treatment with large moleculesNat Rev Clin Oncol20096950751819636328
- BrunsCJLiuWDavisDWVascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastasesCancer200089348849910931447
- PrewettMHuberJLiYAntivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumorsCancer Res199959205209521810537299
- Eli Lilly and Company/ImClone LLCA randomized, double-blind, multicenter phase 3 study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progressive during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidineClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine2012 Available from: http://clinicaltrials.gov/show/NCT01183780. NLM identifier: NCT01183780Accessed April 26, 2013
- National Cancer Institute (NCI)A randomized phase II study of irinotecan and cetuximab with or without the anti-angiogenic antibody, ramucirumab (IMC-1121B), in advanced, K-ras wild-type colorectal cancer following progression on bevacizumab-containing chemotherapy )ClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine2012 Available from: http://clinicaltrials.gov/show/NCT01079780. NLM identifier: NCT01079780Accessed April 26, 2013
- ImClone LLCAn open-label, multicenter, randomized phase 2 study evaluating the safety and efficacy of 5 FU/FA and oxaliplatin (modified FOLFOX 6) in combination with IMC-1121B or IMC-18F1 or without investigational therapy as second line therapy in patients with metastatic colorectal cancer following disease progression on first line irinotecan-based therapyClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine2012 Available from: http://clinicaltrials.gov/show/NCT01111604. NLM identifier: NCT01111604Accessed April 26, 2013
- GrotheyATaberneroJRougierPA randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01183780)J Clin Oncol201230Suppl Abstract TPS3634
- SchwartzJDRowinskyEKYoussoufianHPytowskiBWuYVascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (human antibody targeting vascular endothelial growth factor receptor-1)Cancer2010116Suppl 41027103220127948
- WuYZhongZHuberJAnti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancerClin Cancer Res200612216573658417085673
- BhargavaPRobinsonMODevelopment of second-generation VEGFR tyrosine kinase inhibitors: current statusCurr Oncol Rep201113210311121318618
- IvySPWickJYKaufmanBMAn overview of small-molecule inhibitors of VEGFR signalingNat Rev Clin Oncol200961056957919736552
- PfizerA randomized, phase 2 study of FOLFOX Or FOLFIRI with AG-013736 or bevacizumab (Avastin) in patients with metastatic colorectal cancer after failure of an irinotecan or oxaliplatin-containing first-line regimenClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00615056. NLM identifier: NCT00615056Accessed April 26, 2013
- PfizerA phase II trial of single agent axitinib as maintenance therapy for patients with first line metastatic colorectal cancer (mCRC)ClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine2011 Available from: http://www.clinicaltrials.gov/ct2/show/NCT01490866. NLM identifier: NCT01490866Accessed April 26, 2013
- Boehringer Ingelheim PharmaceuticalsA phase I-II study of BIBF 1120 and FOLFOX compared to bevacizumab and FOLFOX in first line metastatic colorectal cancer patientsClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine2011 Available from: http://clinicaltrials.gov/show/NCT00904839. NLM identifier: NCT00904839Accessed April 26, 2013
- NCIC Clinical Trials GroupA phase III randomized study of Brivanib Alaninate (BMS-582664) in combination with cetuximab (Erbitux®) versus placebo in combination with cetuximab (Erbitux®) in patients with K-RAS wild type tumors previously treated with combination chemotherapy for metastatic colorectal carcinomaClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine2013 Available from: http://clinicaltrials.gov/show/NCT00640471. NLM identifier: NCT00640471Accessed April 26, 2013
- AstraZenecaA randomised, double-blind, multicentre phase II/III study to compare the efficacy of Cediranib (RECENTIN™, AZD2171) in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX), to the efficacy of bevacizumab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (HORIZON III)ClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine2013 Available from: http://clinicaltrials.gov/show/NCT00384176. NLM identifier: NCT00384176Accessed April 26, 2013
- PfizerA multicenter, randomised, double-blind, phase 3 study of sunitinib in metastatic colorectal cancer patients receiving irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) as first line treatmentClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine2013 Available from: http://clinicaltrials.gov/show/NCT00457691. NLM identifier: NCT00457691Accessed April 26, 2013
- AIO-Studien-gGmbHA controlled randomized double-blind multicenter phase II study of FOLFOX6 or FOLFIRI combined with sorafenib versus placebo in second-line metastatic colorectal carcinomaClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine2013 Available from: http://www.clinicaltrials.gov/ct2/show/NCT00889343. NLM identifier: NCT00889343Accessed April 26, 2013
- BayerA randomized, double-blind, placebo-controlled phase III study of regorafenib plus BSC versus placebo plus BSC in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapyClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine2013 Available from: http://clinicaltrials.gov/show/NCT01103323. NLM identifier: NCT01103323Accessed April 26, 2013
- BayerAn open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy (CONSIGN)ClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine2013 Available from: http://clinicaltrials.gov/show/NCT01538680. NLM identifier: NCT01538680Accessed April 26, 2013
- AstraZenecaA phase II, double-blind, placebo controlled, randomized study to assess the efficacy and safety of 2 doses of ZD6474 (Vandetanib) in combination with FOLFOX vs FOLFOX alone for the treatment of colorectal cancer in patients who have failed therapy with an irinotecan and fluoropyrimidine regimenClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine2013 Available from: http://clinicaltrials.gov/show/NCT00500292. NLM identifier: NCT00500292Accessed April 26, 2013
- AstraZenecaA phase II, double blind, placebo controlled, randomised study to assess the efficacy and safety of 2 doses of ZACTIMA™(ZD6474) in combination with FOLFIRI vs FOLFIRI alone for the treatment of colorectal cancer in patients who have failed therapy with anoxaliplatin and fluoropyrimidine containing regimenClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine2011 Available from: http://clinicaltrials.gov/show/NCT00454116. NLM identifier: NCT00454116Accessed April 26, 2013
- Stivarga®(regorafenib) [prescribing information]Wayne, NJBayer HealthCare Pharmaceuticals Inc2013
- WilhelmSMDumasJAdnaneLRegorafenib (BAY73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInt J Cancer2011129124525521170960
- GrotheyAVan CutsemESobreroACORRECT Study GroupRegorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialLancet2013381986330331223177514
- RudgeJSHolashJHyltonDVEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockadeProc Natl Acad Sci U S A200710447183631837018000042
- SobreroAAcklandSClarkeSAVIRI Trial investigatorsPhase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancerOncology200977211311919628950
- NarayanaAGruberDKunnakkatSA clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastomaJ Neurosurg2012116234134522035272
- ChinotOLde La Motte RougeTMooreNAVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiformeAdv Ther201128433434021432029
- KellyWKHalabiSCarducciMRandomized, double-blind, placebo- controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401J Clin Oncol201230131534154022454414
- Sanofi/RegeneronSanofi and Regeneron Announce Regulatory and Clinical Update for Zaltrap® (aflibercept) [press release]Paris: Sanofi/Tarrytown, NYRegeneron452012 Available from: http://en.sanofi.com/Images/30138_20120405_ZALTRAP_BLA_VENICE_en.pdfAccessed November 30, 2012
- National Cancer Institute (NCI)Phase II single arm trial of VEGF trap in patients with recurrent temozolomide-resistant malignant gliomasClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine Available from: http://clinicaltrials.gov/show/NCT00369590. NLM identifier: NCT00369590Accessed April 26, 2013
- National Cancer Institute (NCI)/ImClone LLCAn open label, phase 2 study evaluating the safety and efficacy of IMC-3G3 or IMC-1121B in patients with recurrent glioblastoma multiformeClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine Available from: http://clinicaltrials.gov/show/NCT00895180. NLM identifier: NCT00895180Accessed April 26, 2013
- ImClone LLCA phase 2, multicenter, randomized study of IMC-A12 or IMC-1121B plus mitoxantrone and prednisone in metastatic androgen-independent prostate cancer (AIPC) following disease progression on docetaxel-based chemotherapyClinicalTrials.gov [website on the internet]Bethesda, MDUS National Library of Medicine Available from: http://clinicaltrials.gov/show/NCT00683475. NLM identifier: NCT00683475Accessed April 26, 2013
- ZoppoliGFerrandoVScabiniSOn biomarkers and pathways in rectal cancer: What’s the target?World J Gastrointest Surg201241227527723493582
- BallestreroAGarutiACirmenaGPatient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyondCurr Cancer Drug Targets201212431632822385512